Table 1 Characteristics of included studies.
From: The effect of metformin on survival of patients with pancreatic cancer: a meta-analysis
study | design | tumor stage | size | treatment or metformin exposure in study group | intervention in control group | HR(95% CI) |
|---|---|---|---|---|---|---|
Ambe 2015 | RCS | resectable | 44 | ongoing metformin use | never used metformin | 0.54(0.16–1.86) |
Amin 2016 | RCS | all stages | 1916 | use in the 6 months prediagnosis. | diabetic medications other than metformin | 0.88(0.81–0.96) |
Cerullo 2016 | RCS | resectable | 3396 | use following surgery | no use after surgery | 0.79(0.67–0.93) |
Chaiteerakij 2016 | RCS | all stages | 980 | ever use | ever use | 0.93(0.81–1.07) |
Choi 2016 | RCS | LA; metastatic | 349 | unclear | unclear | 0.70(0.49–1.99) |
Hwang 2013 | RCS | LA; metastatic | 516 | use at any time in the peridiagnosis period | no use during peridiagnosis period | 1.11(0.89–1.38) |
Kordes 2015 | RCT | LA; metastatic | 121 | GE + metformin | GE + placebo | 1.05(0.72–1.55) |
Kozak 2016 | RCS | resectable | 171 | continuous use from first consult to discharge postsurgery | never use or discontinued use | 0.60(0.21–1.67) |
Lee 2016 | RCS | all stages | 237 | cumulative use ≥ 1 month post-diagnosis | use < 1 month or never use | 0.61(0.46–0.81) |
Reni 2016 | RCT | metastatic | 60 | PEXG + metformin | PEXG | 1.56(0.87–2.80) |
Sadeghi 2012 | RCS | all stages | 302 | ever use | never use | 0.64(0.48–0.86) |
